SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting

SignaBlok > News > SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting

SignaBlok > News > SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting

SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for retinopathy of prematurity at the 2017 ARVO Annual Meeting

Vera

View posts by Vera